CASI Pharmeceuticals

Clinical

Clinical Trials

Clinical Trials Currently Enrolling

Please contact the individual trial centers listed below for enrollment information. You may also click on the clinicaltrials.gov link for specific trial information.

Product Candidate Location Principal Investigator Indication Phase Contact
ENMD-2076 University of Colorado Cancer Center Jennifer Diamond, MD Triple-Negative Breast Cancer II Tiffany Colvin (720) 848-0664
ENMD-2076 Indiana University Melvin and Bren Simon Cancer Center Kathy Miller, MD Triple-Negative Breast Cancer II Kathy Miller, MD (317) 944-1690
ENMD-2076 Princess Margaret Hospital Malcolm Moore, MD Albiruni R.A. Razak, MD Advanced/Metastatic Soft Tissue Sarcoma II Mandeep Grewal (416) 946-4501 ext. 3039
ENMD-2076 Multi-center Amit M. Oza, MD Ovarian Clear Cell Carcinoma II Stephanie Capobianco, B.Sc.,416-946-4501 ext. 5185

Ongoing Trials, Enrollment Closed

Product Candidate Location Principal Investigator Indication Phase
ENMD-2076 University of Colorado and Dana-Farber Cancer Institute Dr. Wells Messersmith & Dr. Geoffrey Shaprio Advanced Cancers I

Completed Trials

Product Candidate Location Principal Investigator Indication Phase
MKC-1 Princess Margaret Hospital Dr. Karen Yee Leukemia I
Panzem Preston Robert Tisch Brain Tumor Center at Duke University Medical Center Dr. Annick Desjardins Glioblastoma Multiforme (GBM) II
Panzem Multi-Center Trial Dr. Glenn Liu Renal Cell Carcinoma II
MKC-1 Multi-Center Trial Dr. Nasser H. Hanna Advanced Cancer and Non-Small Cell Lung Cancer (NSCLC) I / II
Panzem Multi-Center Trial Dr. Glenn Liu Hormone-Refractory Prostate Cancer II
MKC-1 Multi-Center Trial Advanced and Metastatic Breast Cancer II
Panzem Duke University Medical Center Dr. Kimberly L. Blackwell Metastatic Breast Cancer Ib
Panzem Indiana University Cancer Center, Indianapolis, IN Dr. Christopher J. Sweeney Advanced Cancer Ib (Part B)
ENMD-1198 University of Colorado Cancer Center, Aurora, CO Dr. Ross Camidge Advanced Cancer I
Panzem Dana-Farber Cancer Institute, Boston, Massachusetts Dr. Matthew Kulke Carcinoid Cancer II
Panzem® University of Wisconsin Comprehensive Cancer Center (UWCCC), Madison, WI Dr. George Wilding Advanced Cancer Ib (Part B)
Panzem Multi-Center Trial Dr. Daniela E. Matei Ovarian Cancer II
Panzem Brain Tumor Center at Duke University Medical Center, Durham, NC Dr. David A. Reardon Brain Cancer II
Panzem University of Wisconsin Comprehensive Cancer Center (UWCCC), Madison, WI Dr. George Wilding Advanced Cancer Ib (Part A)
Panzem Indiana University Cancer Center, Indianapolis, IN Dr. Christopher J. Sweeney Advanced Cancer Ib (Part A)
Panzem Mayo Clinic, Rochester, MN Dr. Vincent Rajkumar Multiple Myeloma II
Panzem Dana-Farber Cancer Institute, Boston, MA Dr. Paul Richardson Multiple Myeloma II
Panzem * National Cancer Institute, Bethesda, MD Dr. William D. Figg, Dr. William Dahut Advanced Solid Tumors I
Panzem ** Mayo Clinic, Rochester, MN Dr. Charles Erlichman Advanced Solid Tumors I
Panzem University of Wisconsin, Madison, WI Dr. George Wilding Prostate Cancer II
Panzem Indiana University Cancer Center, Indianapolis, IN Dr. Chris Sweeney, Dr. George Sledge Prostate Cancer II
Panzem Indiana University Cancer Center, Indianapolis, IN Dr. Kathy Miller , Dr. George Sledge Metastatic Breast Cancer I
Panzem Indiana University Cancer Center, Indianapolis, IN Dr. Kathy Miller , Dr. George Sledge Metastatic Breast Cancer I
MKC-1 Multi-center Dr. Eunice Kwak Pancreatic Cancer II
MKC-1 Multi-center Dr. Amit Oza Ovarian/Endometrial Cancers II
MKC-1 University of Wisconsin Glenn Liu, M.D. Advanced Cancer I
ENMD-2076 Indiana University Melvin and Bren Simon Cancer Center Sherif Farag, M.D. Multiple Myeloma I
ENMD-2076 Princess Margaret Hospital Dr. Karen Yee Leukemia I
ENMD-2076 Princess Margaret Hospital Amit Oza, M.D. Ovarian Cancer II
ENMD-2076 Dana-Farber /Harvard Cancer Center Ursula Matulonis, M.D. Ovarian Cancer II
ENMD-2076 Indiana University Melvin and Bren Simon Cancer Center Daniela Matei, MD Ovarian Cancer II
ENMD-2076 University of Chicago Medical Center Gini Fleming, MD Ovarian Cancer II
ENMD-2076 Memorial Sloan-Kettering Cancer Center William Tew, MD Ovarian Cancer II
ENMD-2076 University of Colorado Cancer Center Kian Behbakht, MD Ovarian Cancer II
ENMD-2076 Celerion, Inc. Dennis Swearingen, MD Ovarian Clear Cell Carcinoma I

* NCI-sponsored trial. CASI Pharmaceuticals provided only the study drug for this trial.
** NCI-sponsored trial. CASI Pharmaceuticals provided only the study drug for this trial.

About Us

A leading US-headquartered, NASDAQ-listed, biopharmaceutical company targeting the global market, with a focus on China.

Learn More

In the News

EntreMed leverages best of China and the West and seeks to expand pipeline.

Read Article →

Poster

Phase II Study of Oral ENMD-2076 Administered to Patients (pts) With Advanced Soft Tissue Sarcoma

Download →

Poster

Phase II Study of Oral ENMD-2076 Administered to Patients with Ovarian Clear Cell Carcinoma

Download →